Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/ Association of Coloproctologists of Great Britain and Ireland (ACPGBI)/ United Kingdom Cancer Genetics Group (UKCGG)

These guidelines are primarily aimed at healthcare professionals and address:

  • Who should have surveillance?
  • When should surveillance take place?
  • What else can we do to prevent cancer?
  • What kind of surgery should we perform in people with hereditary cancer risk?
  • Who is eligible for gene testing, and what kind of testing should we perform?

The St Mark’s Centre for Familial Intestinal Cancer (incorporating the Polyposis Registry and Family Cancer Clinic) 

The St Mark’s Centre for Familial Intestinal Cancer (incorporating the Polyposis Registry and Family Cancer Clinic) is run by a team of specialists consisting of Colorectal Surgeons, Gastroenterologists, Nurse Practitioners, Nurse Specialists and Administrators. The team works together to ensure prompt diagnosis and surveillance of patients with a genetic condition associated with bowel cancer or from a family at high risk of bowel and other cancers.

Breast Cancer Treatment’s Collateral Damage – Let’s Talk about it….

Citizenship rights and obligations

In my view as a citizen of Ireland I have certain rights and obligations.

One of my obligations is to do my best to protect myself and society.

I want people to have access to proper care in our Health system.

Nobody wants a situation where you can not get access to an intensive care bed.

The result of people not receiving a covid vaccination and contracting Covid -will ensure an intensive care bed usage way in excess of what the requirement should be.

Everyone suffers…

Implementing Lynch syndrome testing and surveillance pathways

Lynch Syndrome is the most common form of hereditary colorectal cancer.

By implementing Lynch syndrome pathways nationally for both colorectal and endometrial cancer there is the opportunity to detect many of these at an earlier stage and also prevent cancers through risk reduction treatments and appropriate surveillance routes.

Guidance on management of Lynch syndrome published by NHS UK (July 2021).

Click to access B0622-implementing-lynch-syndrome-testing-and-surveillance-pathways.pdf

PSA Screening for Aggressive Prostate Cancer Supported in Men With Lynch Syndrome

Men carrying MSH2 and MSH6 pathogenic variants, which are associated with Lynch syndrome, were found to have a higher incidence of prostate cancer compared with age-matched non-carrier individuals, supporting the value of annual, targeted prostate-specific antigen (PSA) screening from age 40 to identify men with clinically significant prostate cancer, according to the initial results of the IMPACT study (NCT00261456) that were published in The Lancet Oncology.1

https://www.onclive.com/view/psa-screening-for-aggressive-prostate-cancer-supported-in-men-with-lynch-syndrome-associated-pathogenic-variants

Keeping Patients Up to Date After Genetic Testing

“A patient can have the most thorough and accurate genetic testing available, but if that information is not integrated into their health care, that testing is meaningless. Or worse, if that testing is not interpreted correctly, it can be harmful”

Should children be Tested for Hereditary Syndromes?

“It is generally not a good idea to genetically test minor children for hereditary cancer syndromes, such as Lynch syndrome or BRCA, unless their family medical history warrants it.”

https://www.curetoday.com/view/should-children-be-tested-for-hereditary-cancer-syndromes-?fbclid=IwAR12H4WIHzF5Y-FbmD-9wOOSfzoTKMqZSFO6NQtfxlYLPnuXLJ-Z-CTnBYw